Sorrento Therapeutics, Inc.
Simbolis: SRNE
NASDAQ
0.014
USDRinkos kaina šiandien
-0.0174
P/E santykis
-0.0016
PEG koeficientas
7.72M
MRK kapitalizacija
- 0.00%
DIV pajamingumas
Sorrento Therapeutics, Inc. (SRNE) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 50 | 126.9 | 56.5 | ||||||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 26.3 | 90.2 | 0 | ||||||||||||||||||||
balance-sheet.row.net-receivables | 0 | 24.5 | 18.7 | 15.5 | ||||||||||||||||||||
balance-sheet.row.inventory | 0 | 10 | 8.1 | 1.8 | ||||||||||||||||||||
balance-sheet.row.other-current-assets | 0 | 3.1 | 7.5 | 3.7 | ||||||||||||||||||||
balance-sheet.row.total-current-assets | 0 | 96.4 | 173 | 86.2 | ||||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 138.4 | 126.5 | 73.9 | ||||||||||||||||||||
balance-sheet.row.goodwill | 0 | 80.3 | 79.5 | 43.6 | ||||||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 136.9 | 259.7 | 73.7 | ||||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 217.2 | 339.2 | 117.2 | ||||||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 17.2 | 51.3 | 256.4 | ||||||||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 3.7 | 4.8 | 2 | ||||||||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 376.5 | 521.8 | 449.6 | ||||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-assets | 0 | 472.8 | 694.8 | 535.8 | ||||||||||||||||||||
balance-sheet.row.account-payables | 0 | 47.5 | 27.4 | 24.7 | ||||||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 30.2 | 43.5 | 26.8 | ||||||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 104.3 | 194.1 | 142.6 | ||||||||||||||||||||
Deferred Revenue Non Current | 0 | 7.1 | 118.9 | 113.2 | ||||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||||||||||
balance-sheet.row.other-current-liab | 0 | 249.6 | 67.4 | 40.5 | ||||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 166.6 | 477.2 | 298.6 | ||||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 99.1 | 95 | 53.9 | ||||||||||||||||||||
balance-sheet.row.total-liab | 0 | 494.5 | 616.7 | 395.1 | ||||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.common-stock | 0 | 0.1 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.retained-earnings | 0 | -1959.4 | -1386.6 | -958.3 | ||||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 1.5 | 1 | 0.5 | ||||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 1939.3 | 1464.3 | 1122.9 | ||||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | -18.6 | 78.7 | 165.2 | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 472.8 | 694.8 | 535.8 | ||||||||||||||||||||
balance-sheet.row.minority-interest | 0 | -3.1 | -0.6 | -24.4 | ||||||||||||||||||||
balance-sheet.row.total-equity | 0 | -21.7 | 78.1 | 140.7 | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||||||||||
Total Investments | 0 | 43.5 | 141.5 | 256.4 | ||||||||||||||||||||
balance-sheet.row.total-debt | 0 | 134.5 | 237.6 | 169.4 | ||||||||||||||||||||
balance-sheet.row.net-debt | 0 | 110.9 | 200.9 | 112.9 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -577.8 | -429.1 | -314.4 | ||||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 13.2 | 12.5 | 11 | ||||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | -1.8 | -35.9 | -2.1 | ||||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 74.8 | 90.2 | 31.4 | ||||||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | 69.6 | -2.8 | 3.8 | ||||||||||||||||||||
cash-flows.row.account-receivables | 0 | -5.7 | -3 | -1.1 | ||||||||||||||||||||
cash-flows.row.inventory | 0 | -9.5 | 8.6 | 10.2 | ||||||||||||||||||||
cash-flows.row.account-payables | 0 | 9.9 | -3.9 | -3.7 | ||||||||||||||||||||
cash-flows.row.other-working-capital | 0 | 74.9 | -4.6 | -1.7 | ||||||||||||||||||||
cash-flows.row.other-non-cash-items | 0 | 128.1 | 83.4 | 110.8 | ||||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -13.7 | -8.9 | -37.6 | ||||||||||||||||||||
cash-flows.row.acquisitions-net | 0 | -14.9 | -36 | -2.3 | ||||||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 124.8 | 0 | ||||||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -28.5 | 79.8 | -39.9 | ||||||||||||||||||||
cash-flows.row.debt-repayment | 0 | -188.3 | -85.7 | -205.6 | ||||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 402.3 | 201.8 | 317.9 | ||||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | -55 | ||||||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 97.7 | 65.2 | 116.9 | ||||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 311.7 | 181.3 | 174.2 | ||||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | -2.4 | 0.8 | 0.9 | ||||||||||||||||||||
cash-flows.row.net-change-in-cash | 0 | -13 | -19.8 | -24.3 | ||||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 23.6 | 36.7 | 56.5 | ||||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 36.7 | 56.5 | 80.8 | ||||||||||||||||||||
cash-flows.row.operating-cash-flow | 0 | -293.9 | -281.8 | -159.5 | ||||||||||||||||||||
cash-flows.row.capital-expenditure | 0 | -13.7 | -8.9 | -37.6 | ||||||||||||||||||||
cash-flows.row.free-cash-flow | 0 | -307.5 | -290.7 | -197.1 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 62.8 | 52.9 | 40 | ||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 33.5 | 13 | 9.9 | ||||||||||||||||||||
income-statement-row.row.gross-profit | 0 | 29.4 | 39.9 | 30 | ||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-expenses | 0 | 4.3 | 4.1 | 4.1 | ||||||||||||||||||||
income-statement-row.row.operating-expenses | 0 | 407.9 | 407.9 | 231.6 | ||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 441.3 | 420.9 | 241.5 | ||||||||||||||||||||
income-statement-row.row.interest-income | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 8.6 | 10.2 | 20.2 | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -183.2 | -94.5 | -109.1 | ||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 4.3 | 4.1 | 4.1 | ||||||||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | -183.2 | -94.5 | -109.1 | ||||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 8.6 | 10.2 | 20.2 | ||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 14 | -15.4 | 9.7 | ||||||||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.operating-income | 0 | -378.5 | -368 | -201.5 | ||||||||||||||||||||
income-statement-row.row.income-before-tax | 0 | -561.7 | -462.5 | -310.6 | ||||||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | -2.4 | -33.5 | -2 | ||||||||||||||||||||
income-statement-row.row.net-income | 0 | -559.3 | -429 | -308.6 |
Dažnai užduodami klausimai
Kas yra Sorrento Therapeutics, Inc. (SRNE) bendras turtas?
Sorrento Therapeutics, Inc. (SRNE) bendras turtas yra 472840000.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra N/A.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra 0.416.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra -0.323.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra -9.463.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra -5.619.
Kas yra Sorrento Therapeutics, Inc. (SRNE) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra -559331000.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 134504000.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 407888000.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra 0.000.